Open access
Open access
Powered by Google Translator Translator

Emergency Medicine

Cohort Study: Patient factors associated with appendectomy within 30 days of initiating antibiotic treatment for appendicitis – the presence of an appendicolith was associated with a nearly 2-fold increased risk of undergoing appendectomy within 30 days.

13 Jan, 2022 | 08:39h | UTC

Patient Factors Associated With Appendectomy Within 30 Days of Initiating Antibiotic Treatment for Appendicitis – JAMA Surgery (free for a limited period)

Invited commentary: Appendicoliths, Antibiotic Treatment Failure, and Appendectomy—Is the Glass Half Full or Half Empty? – JAMA Surgery

 


The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – in the absence of contraindications, use therapeutic-dose anticoagulation with low molecular weight heparin for hospitalized patients not in the ICU who have a D-dimer above the upper limit of normal.

12 Jan, 2022 | 09:11h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – NIH COVID-19 Treatment Guidelines

 


Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

12 Jan, 2022 | 09:09h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

Commentaries:

Pfizer antiviral pills may be risky with other medications – NBC News

The New COVID-19 Pill, Paxlovid, Interacts with Many Medications: Cardiac Patients Take Note – The Skeptical Cardiologist

See also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines

 


German Guideline: Oxygen therapy in the acute care of adult patients.

12 Jan, 2022 | 08:57h | UTC

German S3 Guideline: Oxygen Therapy in the Acute Care of Adult Patients – Respiration

 


RCT: Among patients younger than 21 years of age with provoked thromboembolism, anticoagulation for 6 weeks was non-inferior vs. 12 weeks on the risk of recurrence and bleeding events.

12 Jan, 2022 | 08:53h | UTC

Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Duration of Anticoagulant Treatment for Acute Provoked Venous Thromboembolism in Pediatric Patients – JAMA (free for a limited period)

 


Review: Management of coagulopathy in bleeding patients.

12 Jan, 2022 | 08:34h | UTC

Management of Coagulopathy in Bleeding Patients – Journal of Clinical Medicine

 


Clinical Guideline: Acute-on-chronic liver failure.

11 Jan, 2022 | 02:43h | UTC

Acute-on-Chronic Liver Failure Clinical Guidelines – American Journal of Gastroenterology

Related: Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU

 

Commentary on Twitter

 


Position Statement: Prehospital surgical airway management.

11 Jan, 2022 | 02:39h | UTC

Prehospital Surgical Airway Management: An NAEMSP Position Statement and Resource Document – Prehospital Emergency Care

 


Special Issue: Peri‐operative and critical care management of the brain ‐ current evidence.

11 Jan, 2022 | 02:36h | UTC

Homepage: Special Issue:Peri‐operative and critical care management of the brain ‐ current evidence – Anaesthesia

Editorials:

In search of the perfect outcome in neuroanaesthesia and neurocritical care

Anaesthesia and the older brain: what should we do?

Review Articles:

Implications of nocebo in anaesthesia care

Chronic subdural haematoma: the role of peri-operative medicine in a common form of reversible brain injury

Acute peri-operative neurocognitive disorders: a narrative review

Pragmatic sedation strategies to prevent secondary brain injury in low-resource settings

Delirium and COVID-19: a narrative review of emerging evidence

Anaesthesia for mechanical thrombectomy: a narrative review

Clinical applications of point-of-care ultrasound in brain injury: a narrative review

Management of status epilepticus: a narrative review

Evidence-based strategies to reduce the incidence of postoperative delirium: a narrative review

Management of traumatic brain injury: a narrative review of current evidence

Peri-operative neurological monitoring with electroencephalography and cerebral oximetry: a narrative review

Peri-operative management of patients with Parkinson’s disease

 


Review: Rapid diagnostic testing for SARS-CoV-2.

11 Jan, 2022 | 01:34h | UTC

Rapid Diagnostic Testing for SARS-CoV-2 – New England Journal of Medicine

 


Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19.

11 Jan, 2022 | 01:26h | UTC

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 – Covid Advisory for Ontario

 

Commentary on Twitter

 


New CDC Guidance shortens isolation and quarantine period for Covid-19; patients that tested positive should isolate for 5 days and, if asymptomatic after this period, can leave isolation if they can continue to mask for 5 days to minimize the risk of infecting others.

9 Jan, 2022 | 01:13h | UTC

CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population – Centers for Disease Control and Prevention

See also: Quarantine and Isolation – Centers for Disease Control and Prevention

Commentaries:

Facing criticism, CDC updates Covid-19 isolation recommendations with guidance on testing – CNN

CDC posts rationale for shorter isolation, quarantine – Associated Press

Covid-19: CDC shortens isolation period as US cases hit record high – The BMJ

Shortened CDC COVID isolation guide draws sharply mixed reviews – CIDRAP

New CDC isolation guidelines raise concerns among health experts – NPR

CDC Reduces Recommended Isolation Time for People With COVID-19 – HealthDay

COVID isolation and quarantine period for general population shortened by CDC – News Medical

CDC shortens recommended Covid-19 isolation and quarantine time – CNN

CDC cuts the recommended isolation and quarantine periods for coronavirus infections – NPR

US officials recommend shorter COVID isolation, quarantine – Associated Press

See new recommendations from other countries:

France cuts isolation times and plans crackdown on unvaccinated amid record surge in Covid cases – CNN

Covid: Self-isolation cut from 10 days to seven with negative tests – BBC

 


[Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

8 Jan, 2022 | 23:28h | UTC

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma – medRxiv

News release: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine

Commentary: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science

 


RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

17 Dec, 2021 | 09:52h | UTC

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)

 


NICE Guideline | Acute heart failure: diagnosis and management.

17 Dec, 2021 | 08:48h | UTC

Acute heart failure: diagnosis and management – National Institute for Health and Care Excellence

Related: #ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

 


Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021.

17 Dec, 2021 | 08:36h | UTC

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Commentary on Twitter

 


Autoimmune encephalitis after SARS-CoV-2 infection: case frequency, findings, and outcomes.

16 Dec, 2021 | 09:47h | UTC

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

 

Commentary on Twitter

 


Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

16 Dec, 2021 | 09:52h | UTC

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Related:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 


[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

15 Dec, 2021 | 08:46h | UTC

News release: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Commentaries:

Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT

Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press

Related:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

 

Commentary on Twitter (thread – click for more)

 


Position Paper: Diagnosis, management, and prevention of button battery ingestion in childhood.

15 Dec, 2021 | 08:32h | UTC

Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood: A European Society for Paediatric Gastroenterology Hepatology and Nutrition Position Paper – Journal of Pediatric Gastroenterology and Nutrition

Visual summary: Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood

 

Commentary on Twitter (thread – click for more)

 


Review: Diagnosis and management of acute appendicitis in adults.

15 Dec, 2021 | 08:28h | UTC

Diagnosis and Management of Acute Appendicitis in Adults: A Review – JAMA (free for a limited period)

Author Interview: Current Management of Acute Appendicitis: Antibiotics or Surgical Intervention

Commentary: Antibiotics can be first-line therapy for uncomplicated appendicitis cases – Duke University Medical Center

 


How to recognize and manage COVID-19-associated coagulopathy.

13 Dec, 2021 | 09:45h | UTC

How to recognize and manage COVID-19-associated coagulopathy – Hematology, ASH Education Program

 


COVID-19 and thrombosis: searching for evidence.

13 Dec, 2021 | 09:47h | UTC

COVID-19 and thrombosis: searching for evidence – Hematology, ASH Education Program

 


M-A: Performance of the European Society of Cardiology 0/1-hour, 0/2-hour, and 0/3-hour algorithms for rapid triage of acute myocardial infarction.

10 Dec, 2021 | 10:09h | UTC

Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction: An International Collaborative Meta-analysis – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentaries:

Rapid ESC hs-cTn Algorithms Best 3-Hour Protocol for MI Rule-out: Meta-analysis – TCTMD

Performance of ESC 0/1-, 0/2-, 0/3-Hour Algorithms for AMI Compared – HealthDay

 

Commentary on Twitter

 


M-A: Intravenous diltiazem vs. metoprolol for atrial fibrillation with rapid ventricular rate.

10 Dec, 2021 | 10:05h | UTC

Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis – The American Journal of Emergency Medicine (link to abstract – $ for full-text)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.